India · Delayed Price · Currency is INR Mono Pharmacare Statistics
Total Valuation
Mono Pharmacare has a market cap or net worth of INR 353.37 million. The enterprise value is 882.35 million.
| Market Cap | 353.37M |
| Enterprise Value | 882.35M |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Mono Pharmacare has 17.67 million shares outstanding. The number of shares has increased by 15.09% in one year.
| Current Share Class | 17.67M |
| Shares Outstanding | 17.67M |
| Shares Change (YoY) | +15.09% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 56.72% |
| Owned by Institutions (%) | n/a |
| Float | 7.65M |
Valuation Ratios
The trailing PE ratio is 11.44.
| PE Ratio | 11.44 |
| Forward PE | n/a |
| PS Ratio | 0.21 |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.31, with an EV/FCF ratio of -19.48.
| EV / Earnings | 28.55 |
| EV / Sales | 0.52 |
| EV / EBITDA | 11.31 |
| EV / EBIT | 11.50 |
| EV / FCF | -19.48 |
Financial Position
The company has a current ratio of 2.07, with a Debt / Equity ratio of 1.71.
| Current Ratio | 2.07 |
| Quick Ratio | 0.81 |
| Debt / Equity | 1.71 |
| Debt / EBITDA | 6.86 |
| Debt / FCF | -11.83 |
| Interest Coverage | 2.16 |
Financial Efficiency
Return on equity (ROE) is 10.46% and return on invested capital (ROIC) is 6.22%.
| Return on Equity (ROE) | 10.46% |
| Return on Assets (ROA) | 5.02% |
| Return on Invested Capital (ROIC) | 6.22% |
| Return on Capital Employed (ROCE) | 13.40% |
| Revenue Per Employee | 14.65M |
| Profits Per Employee | 268,713 |
| Employee Count | 115 |
| Asset Turnover | 1.76 |
| Inventory Turnover | 3.12 |
Taxes
In the past 12 months, Mono Pharmacare has paid 13.57 million in taxes.
| Income Tax | 13.57M |
| Effective Tax Rate | 30.41% |
Stock Price Statistics
The stock price has increased by +19.62% in the last 52 weeks. The beta is -1.83, so Mono Pharmacare's price volatility has been lower than the market average.
| Beta (5Y) | -1.83 |
| 52-Week Price Change | +19.62% |
| 50-Day Moving Average | 22.74 |
| 200-Day Moving Average | 24.78 |
| Relative Strength Index (RSI) | 40.53 |
| Average Volume (20 Days) | 4,700 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mono Pharmacare had revenue of INR 1.68 billion and earned 30.90 million in profits. Earnings per share was 1.75.
| Revenue | 1.68B |
| Gross Profit | 160.72M |
| Operating Income | 76.76M |
| Pretax Income | 44.63M |
| Net Income | 30.90M |
| EBITDA | 78.04M |
| EBIT | 76.76M |
| Earnings Per Share (EPS) | 1.75 |
Balance Sheet
The company has 6.98 million in cash and 535.60 million in debt, giving a net cash position of -528.63 million or -29.92 per share.
| Cash & Cash Equivalents | 6.98M |
| Total Debt | 535.60M |
| Net Cash | -528.63M |
| Net Cash Per Share | -29.92 |
| Equity (Book Value) | 312.34M |
| Book Value Per Share | 17.66 |
| Working Capital | 562.12M |
Cash Flow
In the last 12 months, operating cash flow was -43.03 million and capital expenditures -2.26 million, giving a free cash flow of -45.29 million.
| Operating Cash Flow | -43.03M |
| Capital Expenditures | -2.26M |
| Free Cash Flow | -45.29M |
| FCF Per Share | -2.56 |
Margins
Gross margin is 9.54%, with operating and profit margins of 4.56% and 1.83%.
| Gross Margin | 9.54% |
| Operating Margin | 4.56% |
| Pretax Margin | 2.65% |
| Profit Margin | 1.83% |
| EBITDA Margin | 4.63% |
| EBIT Margin | 4.56% |
| FCF Margin | n/a |
Dividends & Yields
Mono Pharmacare does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.09% |
| Shareholder Yield | -15.09% |
| Earnings Yield | 8.74% |
| FCF Yield | -12.82% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mono Pharmacare has an Altman Z-Score of 2.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.93 |
| Piotroski F-Score | 4 |